Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.43 |
| ▸ | NPC1 | O15118 | 11/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 6/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | PKM | P14618 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KLF5 | Q13887 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213793 | 0.88 | RAB9A (0.43) | RAB9ANPC1KMT2AMEN1RXFP1 | |
| Hydrochloric Acid SCHEMBL215093 | 0.87 | RAB9A (0.42) | RAB9ANPC1KMT2AMEN1RXFP1 | |
| SCHEMBL213387 | 0.86 | RAB9A (0.49) | RAB9ANPC1KMT2AMEN1RXFP1 | |
| SCHEMBL214823 | 0.81 | CHEK2 (0.35) | RAB9ANPC1KMT2AMEN1RXFP1 | |
| SCHEMBL216260 | 0.81 | CHEK2 (0.35) | RAB9ANPC1KLF5RPS6KA2IRAK4 | |
| Hydrochloric Acid SCHEMBL213800 | 0.81 | CHEK2 (0.35) | RAB9ANPC1KMT2AMEN1RXFP1 | |
| Hydrochloric Acid SCHEMBL216946 | 0.81 | TOP2A (0.35) | RAB9ANPC1KLF5RPS6KA2IRAK4 | |
| SCHEMBL214697 | 0.77 | KDM1A (0.42) | NPC1SMN1; SMN2MAPTTP53CYP3A4 | |
| SCHEMBL214143 | 0.75 | KDM1A (0.42) | SMN1; SMN2LMNAMAPTTP53CYP3A4 | |
| SCHEMBL214620 | 0.75 | CHEK2 (0.39) | RAB9ANPC1KMT2AMEN1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | claimed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | claimed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | RAB9A 2213/4885NPC1 3307/4885KMT2A 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.